Core Viewpoint - Proya (603605.SH) has become the first domestic beauty brand to surpass 10 billion in revenue but is currently facing pressure from slowing performance [1][2] Financial Performance - In the first half of 2025, Proya reported revenue and net profit attributable to shareholders of 5.362 billion and 799 million respectively, representing year-on-year growth of 7.21% and 13.8% [1] - The second quarter showed a significant slowdown, with revenue of 3.003 billion, a year-on-year increase of only 6.49%, down over 30 percentage points compared to the same period in 2024 [1] - The main brand's revenue declined slightly by 0.08% to 3.979 billion in the first half of 2025, compared to a growth rate of 38% in the same period last year [5] Marketing Strategy - Proya has significantly increased its marketing expenditures, signing at least three top celebrities as brand ambassadors in 2025, which is more than the total of the past five years [1][9] - Marketing expenses reached 2.659 billion in the first half of 2025, a year-on-year increase of 13.64% [7] - The company is focusing on cost control, with operating costs down over 5% year-on-year to 1.427 billion [1][11] Competitive Landscape - Proya is set to compete with its peer, Shiseido's parent company, Up Beauty (2145.HK), which reported a revenue growth rate of 16% in the first half of 2025 [3][15] - Proya's market share is currently around 2%, indicating significant room for growth compared to mature markets [6] Future Plans - Proya is planning to list on the Hong Kong Stock Exchange, aiming to enhance its international strategy and financing capabilities [13][14] - The company has identified potential acquisition targets to boost its performance, with a goal of increasing its overall revenue to 35 billion from its own brands and 15 billion through acquisitions over the next decade [15][16]

Core Insights - The company reported a total revenue of 53.56 billion yuan for the first half of 2025, reflecting a year-on-year increase of 7.24% compared to 2024 and 21.09% compared to 2023 [1] Channel Breakdown - Online revenue reached 51.09 billion yuan, showing a growth of 9.17% year-on-year from 2024 and 23.68% from 2023, with a significant contribution of 95.39% to total revenue [1] - Offline revenue was only 2.47 billion yuan, which represents a decline of 21.49% compared to 2024 and 13.63% compared to 2023 [1] Brand Performance - Revenue from various brands in the first half of 2025 included: - Proya: 39.79 billion yuan - Caitang: 7.05 billion yuan - OR: 2.79 billion yuan - Yuefuti: 1.66 billion yuan - Original Pot: 0.97 billion yuan [4] - By product category, skincare (including cleansing) generated 41.99 billion yuan, color cosmetics brought in 8.37 billion yuan, and hair care products accounted for 3.2 billion yuan [4]

Investment Rating - The report maintains an "Overweight" rating for the industry, with a focus on new consumption sectors such as beauty care, IP derivatives, and gold jewelry [5][29]. Core Insights - The report highlights significant market performance for the week of June 23-27, 2025, with retail, social services, and beauty care sectors increasing by 4.56%, 4.61%, and 1.04% respectively, outperforming the Shanghai Composite Index which rose by 1.91% [14][17]. - Key events include the strategic investment of 3.4 billion yuan by Jianbo Biological into Yangshengtang, and the successful IPO of Yingtong Holdings on the Hong Kong Stock Exchange [3][28]. Summary by Sections Market Performance - The retail, social services, and beauty care sectors ranked 9th, 8th, and 24th among 31 primary industries, with notable increases in sub-sectors such as education, professional chains, and trade, which rose by 7.47%, 7.42%, and 5.2% respectively [14][17]. Key Industry Data and News - In the beauty care sector, significant developments include the entry of Kefu Mei into Malaysia's Watsons, becoming the first Chinese efficacy skincare brand in the region, and the announcement by the National Medical Products Administration regarding the management of cosmetic raw materials [23][24]. - Jianbo Biological's restructuring of its collagen product to a medical device category and the successful listing of Yingtong Holdings are also noteworthy [3][24]. Investment Recommendations - The report recommends focusing on companies such as Shangmei Co., Ltd., Juzhi Biological, Marubi Biological, Runben Co., Ltd., Proya, Chaohongji, Blukoo, and Furuida as potential investment targets within the highlighted sectors [5][29].